Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

NexImmune elects to launch initial public offering
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Bolt Biotherapeutics charges to IPO stage
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Vor Biopharma goes for $150m in IPO
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
Immunocore plots course to $100m IPO
The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
Sana to seek $150m in IPO
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
908 Devices inflates IPO to $150m
The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.
Sonovia sounds out stock market
Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.
WealthNavi navigates its way through $173m IPO
UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.
AbCellera amplifies IPO to $556m
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
AbCellera accomplishes $483m initial public offering
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.

test reg